Previous studies on CML biomarkers primarily focused on BCR-ABL transcript levels or somatic mutations (1), which lack specificity in distinguishing CML from other hematologic malignancies (e.g., AML with monocytic differentiation or MDS with fibrosis). Here, BCR is linked to myelodysplastic syndrome.